MIAMI, Oct. 23, 2015 /PRNewswire/ -- Biorasi today announced their support of the American Kidney Fund and kidney patients by sponsoring the Pairing for Prevention community event. Biorasi has been participating in the development of the leading nephrology drugs and works together with pharmaceutical companies to make drug treatments accessible for the patient population that AKF is committed to serving. The support of the American Kidney Fund represents the direct link between Biorasi's clinical trial development expertise and community health care.

Logo - http://photos.prnewswire.com/prnh/20151022/279805LOGO  

"We are deeply grateful to Biorasi for its generosity," said LaVarne A. Burton, president and chief executive officer of the American Kidney Fund. "As a silver sponsor of A Pairing for Prevention, Biorasi is helping to support the many vital programs we provide not only to people with kidney disease, but also to the millions of Americans who are at risk."

"Biorasi is proud to support the American Kidney Fund. Our team has successfully run numerous nephrology clinical trials and is excited to be a part of the American Kidney Fund community event," says Chairman Boris Reznik, PhD.

About the American Kidney Fund

The American Kidney Fund is dedicated to ensuring that every kidney patient has access to health care, and that every person at risk for kidney disease is empowered to prevent it. As the nation's largest not-for-profit organization serving people with chronic kidney disease, AKF has helped more than 1 million low-income dialysis patients to access lifesaving medical care since the organization's founding in 1971. AKF depends on the generosity of the American public to carry out its mission. Spending 97 cents of every donated dollar on programs and services, AKF consistently receives the highest ratings from the nation's charity watchdog groups. For more information, please visit KidneyFund.org, or connect with AKF on Facebook, Twitter and Instagram.

About:

Biorasi is widely recognized as the Leading Biosimilars CRO. Delivering Clinical Research Optimized™ for Biosimilar clinical trials proves Biorasi succeeds in some of the most complex trials in the industry. TALOS™, our innovative project management and optimization platform guides Biorasi studies to success. Equipped with TALOS™, Biorasi full service project teams have developed numerous drugs, biologics, and devices that received FDA and multi-venue approvals. Biorasi is headquartered in Miami, FL and has regional offices across North America and around the world. www.biorasi.com

Media Contact:

Dominique James

786-388-0700

SOURCE Biorasi

Related Links

http://www.biorasi.com